<DOC>
	<DOC>NCT01674842</DOC>
	<brief_summary>This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients with ER negative, PR negative and HER2 negative breast cancer who have undergone breast-conserving surgery or mastectomy. Primary objective: To assess the safety, tolerability, and maximum tolerated dose (MTD) of cisplatin when given concurrently with radiation therapy for participants with Stage II or III breast cancer who have undergone breast conserving surgery or mastectomy</brief_summary>
	<brief_title>Cisplatin + RT for Triple Negative Breast Cancer</brief_title>
	<detailed_description>This is a phase I dose escalation study of cisplatin and radiation to determine the toxicity of this combined treatment and establish an MTD.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Primary tumor is triple negative breast cancer Breastconserving surgery or mastectomy with surgical excision of all gross disease with negative surgical margins Pathologic or clinical stage II or III disease At least 3 week interval from last chemotherapy administration/breast surgery to radiation (no more than 8 weeks) Pregnant or breastfeeding Prior radiation to breast or ipsilateral regional nodes Ongoing therapy with other investigational agents Hormonal therapy Significant comorbidity Pathologic complete response following preoperative chemotherapy Biopsy proven metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Triple negative</keyword>
	<keyword>Stage II</keyword>
	<keyword>Stage III</keyword>
</DOC>